Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

PURPOSE: Wee1 tyrosine kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk) 1/2 in response to DNA damage. AZD1775 is a first-in-class inhibitor of Wee1 kinase with single-agent antitumor activity in preclinical models. We conducted a phase I study of single-agent AZD1775 in adult pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Do, Khanh, Wilsker, Deborah, Ji, Jiuping, Zlott, Jennifer, Freshwater, Tomoko, Kinders, Robert J., Collins, Jerry, Chen, Alice P., Doroshow, James H., Kummar, Shivaani
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2015
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4606059/
https://ncbi.nlm.nih.gov/pubmed/25964244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.4009
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi